Related by context. All words. (Click for frequent words.) 72 posttransplant 70 allogeneic transplant 69 pancreatic adenocarcinoma 69 allogeneic hematopoietic stem cell 68 hepatectomy 68 haematologic 68 imatinib therapy 68 Doxil ® 68 pretransplant 68 coronary revascularization 68 radioiodine therapy 68 autologous SCT 68 azacitidine 68 β blockers 68 virological response 68 postoperative chemotherapy 67 perioperative mortality 67 pCR 67 liver transplant recipients 67 graft dysfunction 67 cranial irradiation 67 allogeneic SCT 67 postoperative complication 67 complete cytogenetic response 67 chronic GVHD 67 undetectable HBV DNA 67 relapsed MM 67 prospectively defined 67 Ejection Fraction 67 hypoperfusion 67 antithymocyte globulin 67 IPAH 66 PSADT 66 histological subtype 66 platelet reactivity 66 preoperative chemotherapy 66 cinacalcet 66 R0 resection 66 thrombocytopenic 66 heavily pretreated patients 66 bladder carcinoma 66 BEXXAR Therapeutic Regimen 66 antimicrobial prophylaxis 66 radical nephrectomy 66 allogeneic HSCT 66 colorectal liver metastases 66 biochemical relapse 66 reperfusion therapy 66 hemodialysis patients 66 neoadjuvant chemotherapy 66 intravesical therapy 66 CR nPR 66 leukocyte count 66 genotypic resistance 66 liver histology 66 underwent resection 66 posttreatment 66 metastatic malignant 66 CRp 66 prognostic variables 66 CCyR 66 tumor resection 66 decitabine 66 glycated hemoglobin levels 66 allogeneic stem cell 66 renal biopsy 66 myeloablative 66 chemoradiation therapy 66 adrenalectomy 66 elevated ALT 66 Pegylated Liposomal Doxorubicin 66 sustained virological response 66 chemoradiotherapy 66 symptomatic VTE 66 lymphocyte count 66 mg/m2 dose 66 FOLPI 66 AST ALT 66 T1DM 66 fibrinolysis 65 ImmuKnow 65 papillary renal cell carcinoma 65 definite stent thrombosis 65 ipsilateral stroke 65 ER CHOP 65 dose cytarabine 65 remission CR 65 allogeneic transplantation 65 postintervention 65 PASI scores 65 hepatic resection 65 hepatorenal syndrome 65 VTE prophylaxis 65 HGPIN 65 alanine aminotransferase ALT 65 parenteral antibiotics 65 vasopressor 65 adalimumab 65 cytoreduction 65 parathyroidectomy 65 MGd 65 severe neutropenia 65 VT VF 65 eculizumab therapy 65 ara C 65 paroxysmal AF 65 NYHA functional class 65 nephrotoxicity 65 rFVIIa 65 radiochemotherapy 65 KRAS status 65 dose melphalan 65 PSA nadir 65 lymph node dissection 65 cytogenetic response 65 visceral metastases 65 PNH patients 65 CsA 65 HBeAg seroconversion 65 pamidronate 65 DMARD 65 lymphadenectomy 65 tumor recurrence 65 intravenous diuretics 65 pelvic lymphadenectomy 65 EDSS scores 65 serum phosphate 65 seropositivity 65 standard chemotherapy regimen 65 mg kg dose 65 response pCR 65 fluvastatin 65 underwent liver transplantation 65 inotropic 64 nodal metastases 64 epoetin beta 64 debulking surgery 64 neurologic progression 64 Follicular Lymphoma 64 locoregional 64 allogeneic bone marrow 64 renal transplantation 64 lung resection 64 antithrombotic therapy 64 certolizumab 64 riociguat 64 renal allograft 64 LVEF 64 thromboprophylaxis 64 Thrombolysis 64 OPCAB 64 curative resection 64 aspartate aminotransferase AST 64 relapsed AML 64 immunosuppression therapy 64 cytoreductive surgery 64 evaluable subjects 64 antibiotic regimens 64 acute GvHD 64 serum creatinine levels 64 MYLOTARG 64 SCr 64 mCRC patients 64 Xelox 64 mycophenolate mofetil 64 follicular lymphoma FL 64 ALT flares 64 glomerular filtration 64 invasive aspergillosis 64 TACE 64 preintervention 64 eplerenone 64 mRCC 64 dosing cohort 64 T2DM 64 perioperatively 64 FluCAM arm 64 ECOG PS 64 liver metastasis 64 CHOP chemotherapy 64 MCyR 64 dalteparin 64 electrophysiologic 64 azacytidine 64 HIV HCV coinfected 64 TURBT 64 DAS# CRP 64 external beam radiotherapy 64 CMV disease 64 de novo AML 64 cerebral vasospasm 64 lipid lowering therapy 64 haematological 64 EXJADE 64 adjuvant radiotherapy 64 perioperative morbidity 64 transaminase levels 64 distant metastases 64 postoperative mortality 64 systemic corticosteroids 64 cervical carcinoma 64 adjuvant tamoxifen 64 neoadjuvant therapy 64 SLNB 64 allogeneic transplants 64 methotrexate therapy 64 heavily pretreated 64 methotrexate monotherapy 64 histologically confirmed 64 SHPT 64 leukemia AML 64 metastatic lung cancer 64 epoetin alfa 64 oral anticoagulation 64 rt PA 64 virologic response 64 neoadjuvant 64 systemic ALCL 64 Kaplan Meier analysis 64 biochemical recurrence 64 topotecan 64 Crohn Disease Activity 64 gastric carcinoma 64 leukemia ALL 64 virologic failure 64 metastatic RCC 64 liver resection 64 ischemic cardiomyopathy 64 metastatic malignant melanoma 64 colorectal adenoma 64 D dimer 64 imipenem 64 surrogate markers 64 haematopoietic stem cell 64 hematologic toxicity 64 metastatic renal cell carcinoma 64 microalbuminuria 63 beta blocker therapy 63 periprocedural 63 pT2 63 FOLFOX4 63 leukocytosis 63 multivariable analysis 63 HAART regimens 63 p# biomarker 63 ICD implantation 63 multivariable analyzes 63 HBsAg 63 thyroglobulin 63 elevated LDH 63 prostate cancer CaP 63 neoadjuvant treatment 63 rFSH 63 autologous hematopoietic stem cell 63 intracranial hemorrhage ICH 63 CANCIDAS 63 CMV infection 63 adjuvant therapies 63 elective PCI 63 SCIg 63 metastatic lesions 63 nondiabetic patients 63 resected pancreatic cancer 63 XIENCE V PROMUS Stent 63 HBeAg positive patients 63 CIMZIA ™ 63 sustained virologic response 63 transplantation HSCT 63 bronchoalveolar lavage 63 postoperative morbidity 63 acute aortic dissection 63 preserved ejection fraction 63 Hypotension 63 systolic dysfunction 63 immunosuppression 63 adenoma recurrence 63 atrioventricular block 63 severe exacerbations 63 serum IGF 63 galiximab 63 total thyroidectomy 63 operable breast cancer 63 euthyroid 63 reinfarction 63 TKI therapy 63 histologic 63 cytoreductive nephrectomy 63 Circulating tumor cells 63 histologically proven 63 radical retropubic prostatectomy 63 revascularization procedure 63 pT3 63 clinicopathologic 63 multivariate analyzes 63 concomitant medications 63 mycophenolate mofetil MMF 63 octreotide LAR 63 hepatic metastases 63 EBRT 63 atypical Hemolytic Uremic Syndrome 63 nephrectomy 63 Pemetrexed 63 NeoRecormon 63 TNF antagonist 63 docetaxel chemotherapy 63 hepatocellular carcinomas 63 cystectomy 63 HER2 overexpression 63 TORISEL 63 hematologic parameters 63 BARACLUDE ® 63 unstable angina pectoris 63 renal cysts 63 NMIBC 63 MELD scores 63 recurrent GBM 63 GnRH agonists 63 Platinol ® 63 hsCRP levels 63 CDAI 63 timepoints 63 histologic subtype 63 lymphocytosis 63 microsatellite instability 63 ejection fractions 63 candidemia 63 Subgroup analysis 63 epoetin alpha 63 seropositive patients 63 clinico pathological 63 chemoembolization 63 HBeAg 63 SUVmax 63 locoregional recurrence 63 HER2 expression 63 K ras mutations 63 erythropoietic 63 carotid stenosis 63 SSc 63 bypass grafting 63 Coronary Artery Bypass Graft 63 adverse cytogenetics 63 subtrochanteric 63 graft occlusion 63 adjuvant radiation 63 elevated troponin 63 ADPKD 63 prostate carcinoma 63 univariate analysis 63 APTIVUS R 63 carcinoid tumors 63 Liver transplantation 63 tacrolimus ointment 63 stage IIIB 63 warfarin therapy 63 revascularization procedures 63 hepatic cirrhosis 63 cART 63 nilotinib 63 bronchogenic carcinoma 63 sargramostim 63 #F FDG PET 63 dose escalation phase 63 retransplantation 63 biliary tract cancer 63 Hematologic 63 macroalbuminuria 62 troponins 62 efalizumab 62 5-fluorouracil/leucovorin 62 lung metastases 62 perioperative complications 62 viral kinetics 62 GIST tumors 62 haematopoietic 62 VADT 62 left ventricular systolic 62 metastatic neuroendocrine tumors 62 meniscectomy 62 endometrial hyperplasia 62 thyroid carcinoma 62 MGUS 62 glycosylated hemoglobin HbA1c 62 autologous transplants 62 sunitinib 62 pulmonary artery banding 62 HbA 1c levels 62 hyperoxaluria 62 Renal Cell Carcinoma RCC 62 univariate analyzes 62 peginterferon 62 invasive candidiasis 62 baseline LDH 62 gastric adenocarcinoma 62 nonoperative treatment 62 GISTs 62 immunosuppressive regimens 62 metastatic CRC 62 antibody titer 62 Retreatment 62 recurrent glioblastoma multiforme 62 serum calcium levels 62 HCV infected 62 neutropenic 62 ADHF 62 Advagraf 62 LV dysfunction 62 RECIST Response Evaluation Criteria 62 LVNC 62 partial remissions 62 distant metastasis 62 transaminase elevations 62 DAPT 62 oblimersen 62 doxorubicin docetaxel 62 RBC transfusion 62 hemoglobin A1c levels 62 thrombolytic agents 62 AZT zidovudine Retrovir 62 Xanafide 62 irbesartan 62 atherogenic dyslipidemia 62 renal cell carcinomas 62 eribulin mesylate 62 liver biopsies 62 histologic diagnosis 62 DOXIL 62 radical cystectomy 62 chemotherapeutic regimen 62 unfavorable cytogenetics 62 LEUKINE 62 nodal dissection 62 immunosuppressive agents 62 Natalizumab 62 mucosal healing 62 femoral neck fracture 62 troponin T 62 antiangiogenic therapy 62 potent antiretroviral therapy 62 clinically meaningful improvement 62 nicardipine 62 retrospective cohort 62 pimecrolimus cream 62 antiretroviral naïve 62 cytotoxic chemotherapy 62 primary patency 62 advanced adenoma 62 adrenal insufficiency 62 Postoperative complications 62 KRAS mutation 62 refractory AML 62 adenotonsillectomy 62 biologic DMARD 62 transplantation HCT 62 Percutaneous Coronary Intervention 62 Myelodysplastic Syndrome 62 indolent lymphomas 62 cytogenetic responses 62 bevacizumab Avastin 62 lymphocyte counts 62 NGAL 62 cytogenic 62 angiographic outcomes 62 grade cervical intraepithelial 62 concurrent chemoradiation 62 flutamide 62 PEG IFN 62 hydroxyvitamin D levels 62 serum PTH 62 gadobutrol 62 busulfan 62 PROSTVAC VF 62 Fludarabine 62 ABVD 62 IV NSCLC 62 serum lipid levels 62 sorafenib Nexavar 62 thalidomide Thalomid 62 Decitabine 62 immunocompetent 62 insulin detemir 62 calculated creatinine clearance 62 Virologic 62 COPAXONE R 62 urine NGAL 62 canakinumab 62 clinicopathological 62 TMP SMX 62 zoledronic acid 62 inducible nitric oxide synthase 62 ALND 62 androgen deprivation 62 Tumor Response 62 estimated glomerular filtration 62 virologic responses 62 calcineurin inhibitor 62 relapsed SCLC 62 ICD shocks 62 CYPHER Stent 62 breast carcinoma 62 paricalcitol 62 parasitemia 62 neutrophil counts 62 esophageal carcinoma 62 echocardiographic parameters 62 complete cytogenetic 62 postoperative atrial fibrillation 62 serum estradiol 62 insulin glulisine 62 SSc patients 62 acute STEMI 62 kidney allograft 62 F FDG PET 62 alteplase 62 radiotherapy RT 62 pneumonectomy 62 Velcade bortezomib 62 posaconazole 62 fosamprenavir 62 NATRECOR ® 62 tumor histology 62 cTnT 62 EDSS score 62 cancer mCRC 62 tigecycline 62 preoperative PSA 62 Flu Cy 62 NNRTI resistance 62 fallopian tube cancers 62 ribavirin RBV 62 trials RCTs 62 immunosuppressive medications 62 immunosuppressant therapy 62 metastatic GIST 62 metaplasia 62 NIHSS score 62 GH deficiency 62 tumor necrosis 62 interferon ribavirin 62 ß blockers 62 unfractionated heparin UFH 62 gemcitabine carboplatin 62 EUS FNA 62 Solid Tumors criteria 62 ATACAND 62 hip resurfacing arthroplasty 62 clinically evaluable 62 tumor lysis syndrome 62 protease inhibitor PI 62 therapeutic regimens 62 hematological parameters 62 idarubicin 62 corticosteroid therapy 62 bendamustine 62 cranial radiation 61 DAS# scores 61 thrombocytosis 61 MYCAMINE 61 prospective multicenter study 61 gastrointestinal stromal tumors GIST 61 RBC transfusions 61 Allogeneic 61 CTEPH 61 peginterferon alfa 61 reintervention 61 CLL SLL 61 hepatic fibrosis 61 tuberculin skin testing 61 pharmacodynamic PD 61 basal cell nevus syndrome 61 complete remissions 61 temsirolimus 61 AGILECT R 61 renal dysfunction 61 ovarian carcinoma 61 HBeAg negative patients 61 caspofungin 61 thoracoscopic lobectomy 61 Cloretazine 61 Thrombocytopenia 61 FOLFOX6 61 Renal dysfunction 61 B7 H3 61 follicular lymphomas 61 pacemaker implantation 61 HNSCC 61 ependymoma 61 receptor tyrosine kinase inhibitor 61 bolus dose 61 cTnI 61 Index CDAI 61 lactate dehydrogenase LDH 61 peg interferon 61 poor metabolizers 61 Kaplan Meier estimates 61 antihypertensive therapy 61 HIPEC 61 Nesiritide 61 IFN beta 61 ARIXTRA 61 NIHSS 61 allogeneic hematopoietic cell 61 Hydroxyurea 61 hematological relapse 61 myocardial revascularization 61 daunorubicin 61 4mg/kg 61 interferon beta therapy 61 chronic hemodialysis 61 recurrent glioma 61 ALT elevations 61 hemodilution 61 hepatic encephalopathy HE 61 salmeterol fluticasone 61 HBeAg negative 61 KRAS mutations 61 virologic response EVR 61 Primary endpoints 61 Leukemias 61 femoral shaft fracture 61 essential thrombocythemia 61 pulmonary metastases 61 decompensated heart failure 61 noncardiac 61 ACR# response 61 HbF 61 cisplatin chemotherapy 61 mutated KRAS 61 serum HBV DNA 61 overt nephropathy 61 pain palliation 61 fibrinolytic 61 HPA axis suppression 61 Immunosuppression 61 ALI ARDS 61 hemoglobin Hb 61 tirofiban 61 intraobserver 61 myocardial viability 61 platinum refractory 61 artery stenosis 61 intravenous tPA 61 axillary dissection 61 acute leukemias 61 resectable 61 cytopenias 61 cardiac troponin 61 histologically 61 response CCyR 61 lenalidomide Revlimid R 61 advanced neoplasia 61 μmol L 61 oral anticoagulant therapy 61 macrovascular events 61 BRCA2 mutation carriers 61 underwent CABG 61 ertapenem 61 myocardial necrosis 61 hA# 61 cholangiocarcinoma 61 Acute Decompensated Heart Failure 61 clinicopathological features 61 histopathologic examination 61 renal transplants 61 trastuzumab Herceptin ® 61 Lymph node 61 H. pylori eradication 61 glycoprotein IIb IIIa inhibitors 61 clevidipine 61 intravenous dosing 61 SCCHN 61 diagnostic angiography 61 EBUS FNA 61 virological failure 61 serum urate levels 61 urothelial carcinoma 61 carotid artery stenting 61 Acute Coronary Syndromes ACS 61 GnRH agonist 61 temozolomide 61 chest radiographs 61 cytogenetic abnormalities 61 chlorambucil 61 BCG refractory 61 randomized multicenter Phase III 61 postprocedure 61 rebleeding 61 thrombus aspiration 61 calcineurin inhibitors 61 DAS# remission 61 mCi kg 61 Severe Primary IGFD 61 endothelial activation 61 CIMZIA TM certolizumab pegol 61 carotid artery stenosis 61 BRAF mutations 61 colectomy 61 myeloproliferative neoplasms 61 coronary stenosis 61 cardiac dysfunction 61 Hb A1C 61 randomized controlled trials RCTs 61 aminotransferase 61 Hurthle cell 61 STRIDE PD 61 bone scintigraphy 61 prospectively enrolled 61 serum albumin 61 CIMZIA TM 61 histologies 61 Certican 61 refractory ovarian cancer 61 STN stimulation 61 LHRH agonists 61 pancreatic insufficiency 61 onset diabetes mellitus 61 Chronic Myeloid Leukemia 61 fibrinolytic therapy 61 Folfox 61 Subgroup analyzes 61 elevated creatinine 61 ECOG 61 patients evaluable 61 NATRECOR R 61 specific antigen PSA 61 nonmetastatic 61 serum cortisol 61 thromboembolic events 61 alefacept 61 anti Xa 61 sipuleucel T 61 LTBI 61 ECD kidneys 61 lymph node metastasis 61 perfusion abnormalities 61 unstable angina UA 61 crizotinib PF # 61 asymptomatic carotid stenosis 61 FDG PET 61 gefitinib Iressa 61 hematopoietic cancers 61 timepoint 61 moderately emetogenic 61 thrombotic complications 61 stratifying patients 61 lupus nephritis 61 pegfilgrastim 61 tumor regressions 61 mutated K ras 61 pancreatectomy 61 tocilizumab 61 APTIVUS 61 ABCB1 61 autonomic dysfunction 61 TAXUS Stent 61 androgen suppression therapy 61 intravesical 61 radiographic progression 61 NSABP B 61 dose Iluvien 61 NHANES III 61 peritoneal cancer 61 dacarbazine chemotherapy 61 intestinal permeability 61 dacarbazine 61 etoposide 61 immunostaining 61 bivariate analysis 61 pharmacodynamic parameters 61 urothelial cancer 61 chemosensitivity 61 Dasatinib 61 Non inferiority 61 nonalcoholic steatohepatitis NASH 61 anti leukemic 61 CMV reactivation 61 deep venous thromboses 61 serum phosphate levels 61 steroid dexamethasone 61 satraplatin Phase 61 prophylactic cranial irradiation 61 randomized multicenter trial 61 tenecteplase 61 Pegylated Interferon 61 Telintra 61 Clusterin 61 CHAMPION PCI 61 EGFR TKI 61 chorioamnionitis 61 bFGF 61 Randomized Evaluation 61 pegylated interferon alfa 61 anthracycline therapy 61 pomalidomide 61 inhibitor RG# 61 SERCA2a 61 thromboembolic complications 61 potentially hepatotoxic 61 nonmetastatic prostate cancer 61 coinfected patients 61 chemo radiotherapy 61 locoregional disease 61 malignant neoplasm 61 antibiotic prophylaxis 61 Recurrence Score 61 autologous chondrocyte implantation 61 FIRMAGON 61 portal vein thrombosis 61 achieved ACR# 61 MitraClip device 61 androgen suppression 61 hepatic arterial 61 dose cohort 61 microbiological eradication 60 Lp PLA 2 60 malignant neoplasms 60 grade gliomas 60 myelodysplastic syndrome MDS 60 nonfatal MI 60 squamous histology 60 platelet dysfunction 60 atherothrombosis 60 CORE OM 60 reoperations 60 ovarian stimulation 60 HER2 positive metastatic breast 60 Solid Tumors 60 leukemic stem cells 60 neurocognitive function 60 thymoma 60 preoperative diagnosis 60 esophagectomy 60 hepatic enzyme 60 patients undergoing CABG 60 tamoxifen therapy 60 colorectal cancer liver metastases 60 Naive Patients 60 hepatitis C genotype 60 FOLFIRINOX 60 airway hyperresponsiveness 60 node metastases 60 pharmacokinetic PK profile 60 ancrod 60 immunomodulation 60 HAART regimen 60 piperacillin tazobactam 60 receiving VICTRELIS 60 immunosuppressive therapies 60 Viral load 60 MabCampath 60 CIN3 60 prognostic significance 60 rituximab 60 Postoperative 60 PLCO 60 chemoradiation 60 dose dexamethasone 60 achieved CCyR 60 spirometric 60 exploratory endpoints 60 hemodynamically significant 60 stable angina 60 serum testosterone 60 EURIDIS 60 adjuvant trastuzumab 60 colorectal cancer CRC 60 epithelial tumors 60 elacytarabine 60 HBV infections 60 Hyperlipidemia 60 Severe Sepsis 60 resynchronization therapy 60 pretest probability 60 taxane therapy 60 AIR2 Trial 60 PCa 60 virologic 60 thrombophilia 60 Atypical Hemolytic Uremic Syndrome 60 non squamous NSCLC 60 Ranolazine 60 plasma cortisol 60 LDLT 60 vWF 60 vernakalant hydrochloride 60 erlotinib Tarceva ® 60 sentinel lymph node biopsy 60 latent tuberculosis infection 60 endoscopic resection 60 postoperative radiotherapy 60 GP IIb IIIa inhibitors 60 endoscopic remission 60 acute myocardial infarction AMI 60 MULTAQ 60 Helicobacter pylori eradication 60 TEMODAL 60 KRAS mutations occur 60 daily subcutaneous injections 60 surrogate endpoint 60 nonoperative 60 total abdominal hysterectomy 60 echocardiographic 60 tumor shrinkage 60 infective endocarditis 60 baseline HbA1c 60 onset atrial fibrillation 60 Adjuvant chemotherapy 60 inguinal hernia repair 60 ximelagatran 60 stem cell engraftment 60 HLA matched 60 anemia hemoglobin 60 basal cell carcinoma BCC 60 hemoglobin concentration 60 abacavir Ziagen 60 platelet transfusions 60 primary aldosteronism 60 logistic regression analyzes 60 uridine triacetate 60 lanthanum carbonate 60 pegylated interferon alfa 2b 60 prostate adenocarcinoma 60 K ras 60 serum calcium 60 Psoriasis Area 60 nephron sparing surgery 60 rilonacept 60 micafungin 60 atherothrombotic disease 60 neutropaenia 60 trabectedin 60 morphometric vertebral fractures 60 interferon alfa 2b 60 HeFH 60 tapentadol ER 60 APTIVUS r 60 Events MACE 60 pharmacodynamic endpoints 60 liposomal doxorubicin 60 oncologic outcomes 60 intravenous cyclophosphamide 60 oncological outcomes 60 ICD therapy 60 crossclamp 60 juvenile idiopathic arthritis 60 VAPRISOL 60 XELOX 60 recurrent venous thromboembolism 60 venous thromboembolism prophylaxis 60 EoE 60 telomere lengths 60 gemcitabine Gemzar 60 serum creatinine 60 CAMMS# 60 retinal vein occlusion 60 myocardial reperfusion 60 receiving immunosuppressive therapy 60 fosbretabulin 60 demyelinating 60 arteriography 60 pulmonary toxicity 60 immunosuppressive regimen 60 mcg albinterferon alfa 2b 60 follicular NHL 60 anagrelide 60 Adenomas 60 SGPT 60 MALT lymphoma 60 multivariate regression analysis 60 dosage regimens 60 thromboembolic 60 QTc prolongation 60 proliferative retinopathy 60 Cytogenetic 60 PTLD 60 physiologic parameters 60 sternal wound infections 60 polyp recurrence 60 breast carcinomas 60 refractory chronic lymphocytic 60 Bortezomib 60 TEVAR 60 imatinib resistance 60 LRAT 60 epirubicin 60 recanalization 60 pharmacologic stress 60 pulmonary resection 60 VUR 60 Renal Function 60 Myocardial Infarction 60 Cardiotoxicity 60 neutropenic patients 60 acromegalic patients 60 aminotransferases 60 advanced adenomas 60 Dacogen decitabine 60 levosimendan 60 5FU